Woodmont Investment Counsel’s Teva Pharmaceuticals TEVA Stock Holding History

Woodmont Investment Counsel’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-580	Closed	-$27K	–	567
2016 Q3	$27K	Buy	+580	New	+$30.3K	0.01%	326
2016 Q2	–	Sell	-580	Closed	-$31K	–	424
2016 Q1	$31K	Hold	580	–	–	0.01%	315
2015 Q4	$38K	Hold	580	–	–	0.01%	291
2015 Q3	$33K	Hold	580	–	–	0.01%	300
2015 Q2	$34K	Buy	+580	New	+$35.8K	0.01%	301

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Woodmont Investment Counsel's TEVA Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 580 shares — an estimated $27K sold.

Woodmont Investment Counsel first reported a position in TEVA in Q2 2015 and held it in 5 quarters. The position peaked at $38K in Q4 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Woodmont Investment Counsel reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Woodmont Investment Counsel sold 580 Teva Pharmaceuticals shares in Q4 2016, an estimated $27K.
Woodmont Investment Counsel first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Woodmont Investment Counsel's Teva Pharmaceuticals position peaked at $38K in Q4 2015.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.